Patient Preferences Regarding Rheumatoid Arthritis Therapies: A Conjoint Analysis.

ABSTRACT:

Background

Tofacitinib, an oral Janus kinase inhibitor approved for the treatment of rheumatoid arthritis (RA), provides patients with an alternative to subcutaneously or intravenously administered biologic disease-modifying antirheumatic drugs (DMARDs). Little is known about patient preference for novel RA treatments.

Objective

To investigate patient preferences for attributes associated with RA treatments.

Methods

A choice-based conjoint survey was mailed to 1400 randomly selected commercially insured patients (aged 21-80 years) diagnosed with RA, who were continuously enrolled from May 1, 2012, through April 30, 2013, and had ≥2 medical claims for International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis code 714.0 and no previous bi

SUBMITTER: Louder AM 

PROVIDER: S-EPMC4856233 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature